Prognosis of PSA Decline in mCRPC

Significance of PSA Response to Treatment

The National Comprehensive Cancer Network (NCCN) guidelines support Lu-177-PSMA therapy for patients who have received limited docetaxel treatment, representing an evidence-based approach for mCRPC management 1

The stabilization of PSA at 0.173 suggests effective disease control, as PSA doubling time (PSA-DT) is a critical prognostic factor in prostate cancer progression, with patients having slower PSA-DT (stable PSA) experiencing significantly better outcomes regarding development of distant metastases, prostate cancer-specific mortality, and overall mortality 2

The European Association of Nuclear Medicine recommends 4-6 cycles of Lu-177-PSMA therapy at 6-week intervals, with each cycle delivering 5.55-7.4 GBq (150-200 mCi) of radioactivity to PSMA-expressing tumor cells, achieving a significantly higher PSA response rate (66%) compared to cabazitaxel (37%) in patients who had previously received docetaxel 1
Lu-177-PSMA therapy has shown efficacy with fewer grade 3-4 adverse events (33%) compared to alternative treatments like cabazitaxel (53%) in patients who progressed after taxane-based chemotherapy 1

The VISION trial demonstrated that Lu-177-PSMA-617 plus best standard of care significantly improved overall survival (15.3 vs 11.3 months) and radiographic progression-free survival (8.7 vs 3.4 months) compared to standard of care alone, with the American College of Radiology recommending continued Lu-177 therapy beyond two cycles for patients who have not progressed 1

Regular monitoring of hematologic parameters is essential as myelosuppression can be cumulative with additional cycles of Lu-177 therapy, with common side effects including fatigue, dry mouth, nausea, and potential for thrombocytopenia, anemia, and lymphopenia 1

The European Association of Nuclear Medicine and the American College of Radiology recommend considering PSA levels in conjunction with imaging studies such as bone scans and CT to assess treatment response in mCRPC, as PSA levels alone may not always reliably reflect disease status in patients on hormonal therapy 3